Primary Record
Daclatasvir
- In stock
- 2,263 g
- Purity
- 98.4 %
- CAS
- 1009119-64-5
Compound Identifiers & Properties
- CAS
- 1009119-64-5
- PubChem CID
- 25154714
- SMILES
- CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
- Canonical SMILES
- COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
Names & Synonyms
- Daclatasvir
- 1009119-64-5
- Daklinza
- BMS-790052
- Daclatasvir (BMS-790052)
- daclatasivr
- daclatasvirum
- daclatasvir HCl
- -2-yl)carbamate
- Daclatasvir [USAN]
- Daclatasvir (USAN)
- Daclatasvir dihydrochloride
- EBP 883
- daclatasvir hydrochloride
- BMS790052
- DACLATASVIR [MI]
- RefChem:585147
- DACLATASVIR [INN]
- BMS 790052
- Daclatasvir [USAN:INN]
- cc-39
- D09SGV
- EBP-883
- LI2427F9CI
- UNII-LI2427F9CI
- Daclatasvir BMS 790052
- DACLATASVIR [WHO-DD]
- 1214735-16-6
- CHEBI:82977
- MLS006011140
- BMS-790052 dihydrochloride
- MFCD18074519
- C40H50N8O6
- DTXSID901026404
- EBP883
- orb1300958
- SCHEMBL2756027
- CHEMBL2023898
- SCHEMBL17897804
- GTPL11266
- KS-00000XPC
- EX-A410
- J05AP07
- Daclatasvir for system suitability
- BDBM627982
- Daclatasvir for peak identification
- DTXCID901510617
- GLXC-90030
- AMY36655
- AOB87747
- Daclatasvir, 1214735-16-6
- 3503AH
- ABP000738
- BDBM50387084
- EBC-27445
- MFCD17129086
- s1482
- ZINC68204830
- AKOS030524262
- ACN-050889
- CA10002
- CCG-270425
- CS-0588
- DB09102
- RL00957
- BMS-790052/
- CVD-0019437
- NCGC00346533-07
- NCGC00346533-09
- NCGC00346533-14
- AC-28958
- AS-75298
- BC638780
- BMS 790052; EBP 883
- FD158832
- HY-10466
- SMR004702917
- SY069672
- BMS-790052-05
- Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester
- A3257
- A5618
- FT-0771596
- FT-0772670
- NS00072904
- SW219754-1
- X7549
- J2.827.385A
- methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
- A10159
- D10065
- Q-4025
- A897299
- EN300-27736661
- Q5207712
- BRD-K82861010-001-02-5
- dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
- methyl N-[(2S)-1-[(2S)-2-[5-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
- Carbamic acid, N,N'-((1,1'-biphenyl)-4,4'-diylbis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester
- Daclatasvir, 99%, Highly selective HCV NS5A inhibitors - 25MG 25mg
- Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dica
- methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
- methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate
- [(Biphenyl-4,4 -diyl)bis[(1H-imidazole-5,2-diyl)(pyrrolidine-2alpha,1-diyl)[(S)-1-oxo-2-isopropylethylene]]]bis(carbamic acid methyl) ester
- [(Biphenyl-4,4 -diyl)bis[(1H-imidazole-5,2-diyl)[(2S)-pyrrolidine-2,1-diyl][(S)-1-oxo-2-isopropylethylene]]]bis(carbamic acid methyl) ester
- 1009119-65-6
- 4,4 -Bis[2-[(2S)-1-[(S)-2-[(methoxycarbonyl)amino]-3-methylbutyryl]pyrrolidine-2-yl]-1H-imidazole-5-yl]-1,1 -biphenyl
- 5-Pyrimidinecarbonitrile, 4-[[[(3R,5S)-4-[[(trans-4-hydroxycyclohexyl)methyl]amino]tricyclo[3.3.1.13,7]dec-1-yl]methyl]amino]-2-[[[2-(methylthio)-3-pyridinyl]methyl]amino]-, rel-
- 881-759-2
- Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester; BMS 790052; Daclatasvir; Daklinza; EBP 883
- DCV
- Dimethyl ((2S,2'S)-((2S,2'S)-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate
- dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate
- DIMETHYL N,N'-((1,1'-BIPHENYL)-4,4'-DIYLBIS(1H-IMIDAZOLE-5,2-DIYL-((2S)-PYRROLIDINE-2,1-DIYL)((1S)-3-METHYL-1-OXOBUTANE-1,2-DIYL)))DICARBAMATE
- Dimethyl N,N'-(biphenyl-4,4'-diylbis(1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1-diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)))dicarbamate
- Dimethyl N,N'-(biphenyl-4,4'-diylbis{1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1- diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate
- methyl ((S)-1-((S)-2-(4-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan
- methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbama
- methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamat
- methyl [(2s)-1-{(2s)-2-[4-(4'-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1h-imidazol-4-yl}-4-biphenylyl)-1h-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]carbamate
- methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate
- Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate
- methyl N-((2S)-1-((2S)-2-(5-(4-(4-(2-((2S)-1-((2S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
- methyl N-[(2S)-1-[(2S)-2-[4-(4'-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-4-yl}-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
- methyl-N-[(2s)-1-[(2s)-2-[5-[4-[4-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl] pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]phenyl]-1himidazol-2-yl]pyrrolidin-1-yl]3-methyl-1-oxobutan-2-yl]carbamate
- N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
- TE